A phase 1 study demonstrated pharmacokinetic (PK) bioequivalence of the proposed ustekinumab biosimilar SB17 (Samsung Bioepis) to the EU- and US-sourced reference products.
A phase 2 study demonstrated pharmacokinetic (PK) bioequivalence of the proposed ustekinumab biosimilar SB17 (Samsung Bioepis) to the EU- and US-sourced reference products. The authors also reported safety, tolerability, and immunogenicity were “comparable” between the 3 groups.
Image credit: Prostock-studio - stock.adobe.com
Ustekinumab is a monoclonal antibody targeting the p40 subunit of interleukin (IL)-12 and IL-23, cytokines involved in the pathogenesis of several inflammatory diseases. Ustekinumab blunts the inflammatory response by blocking the interaction of IL-12 and IL-23 with a receptor on the surface of natural killer cells and T cells.
The reference product (Stelara) was originally approved to treat moderate to severe plaque psoriasis in the US and European Union (EU) in 2009, and is now approved for several other chronic inflammatory diseases.
Previous analytical and non-clinical studies have established structural, physicochemical, and biological similarity to the reference product, and the current study aimed to compare PK parameters, safety, tolerability, and immunogenicity between SB17 and both the US and EU-sourced reference products in healthy adults.
A total of 201 participants were randomized to receive a single subcutaneous dose of 45 mg of the biosimilar, US reference ustekinumab, and EU reference ustekinumab. The primary PK end points were the area under the concentration-time curve from time zero to infinity (AUCinf) and maximum serum concentration (Cmax). Baseline characteristics of the participants in the 3 groups were “generally comparable,” the authors said, except for body weight which was significantly different between groups.
Primary Pharmacokinetic Endpoints Within Equivalence Margins
The authors noted that each pair of mean serum concentration-time profiles was “superimposable and comparable.” The ratios of geometric least-squares means AUCinf and Cmax were 0.99 and 0.90 for SB17 compared to the EU reference product, 1.01 and 0.94 for SB17 compared to the US reference product, and 1.02 and 1.05 for the EU compared to the US reference product. All 90% CIs for the ratios of AUCinf and Cmax between groups were within the predefined bioequivalence margin of 0.8-1.25.
Since body weight differed between groups, body-weight adjusted analyses were also carried out, and all 90% CIs were within the equivalence margins and contained 1.0. The authors added that all secondary pharmacokinetic endpoints were comparable across the 3 treatment groups.
Safety and Immunogenicity
Rates of treatment-emergent adverse events (TEAEs) were “comparable,” at 69%, 58%, and 66% in the SB17, EU reference, and US reference groups and no deaths or severe TEAEs were reported. The most common TEAE was headache.
There were no significant between-group differences in antidrug antibodies (ADAs) detected between groups, with 27%, 34%, and 34% of the participants receiving SB17, the EU reference product, and the US reference product positive for ADAs. Of participants positive for ADAs at the end of the study, approximately half (54%) were positive for neutralizing antibodies.
The authors concluded this phase 1 study demonstrates “equivalent pharmacokinetics and comparable immunogenicity, tolerability, and safety profiles” of SB17 and both EU and US reference products healthy adults, and said their results support conducting a phase 3 study of the candidate biosimilar in patients with psoriasis.
Reference
Jeong H, Kang T, Lee J, Im S. Comparison of SB17 and reference ustekinumab in healthy adults: A randomized, double-blind, single-dose, phase I study. Int J Clin Pharmacol Ther. 2024;62(5):231-240. doi:10.5414/CP204492
Etanercept Biosimilar Switch Shows Stable Outcomes and Disease Control in RA
May 13th 2025Patients with rheumatoid arthritis (RA) who switched from Enbrel (reference etanercept) to a biosimilar maintained remission, even after their dose was reduced, with no signs of worsening based on clinical scores, ultrasound scans, or lab tests, according to a new study.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs
May 10th 2025Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.